Women with breast cancer and other gynecologic cancers often suffer significant distress and disability from their disease. A practice of meditation-based stress reduction and cognitive-affective-behavioral learning may help women with these conditions decrease their suffering and improve their quality of life.

Further study details as provided by Weill Medical College of Cornell University:

Primary Outcome Measures:

Quality of life will be assessed by within patient differences in the FACT-G (General Functional Assessment of Cancer Treatment Scale), as well as with the disease specific subscales at baseline and at 12 months. [ Time Frame: Subjects will complete questionnaires at baseline and closeout. Patients will participate in the meditation program weekly for 20 weeks. ] [ Designated as safety issue: No ]

Estimated Enrollment:

200

Study Start Date:

May 2003

Estimated Study Completion Date:

March 2010

Estimated Primary Completion Date:

March 2010 (Final data collection date for primary outcome measure)

Intervention Details:

Behavioral: Mindfulness based meditation program

Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.

Other Name: Meditation and Breast Cancer

Detailed Description:

The objective of this project in women recently treated for breast or other gynecologic cancer is to determine whether an intervention program consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning has the potential for reducing disabling distress and improving quality of life in a population vulnerable to the progression or recurrence of disease. Quality of life will be assessed at 12 months.

Eligibility

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Genders Eligible for Study:

Female

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

All women with stage I-III breast or other gynecologic cancer who have received treatment within the preceding year will be eligible for inclusion in the study.

Exclusion Criteria:

Patients who refuse to participate will be excluded

Patients with Metastatic cancer are excluded.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00248911

Locations

United States, New York

Weill Cornell Medical College-New York Hospital

New York, New York, United States, 10065

Sponsors and Collaborators

Weill Medical College of Cornell University

Avon Foundation

Investigators

Principal Investigator:

Mary E Charlson, MD

Weill Medical College of Cornell University

Principal Investigator:

Joseph Loizzo, MD,PhD-interventionist

Center for Complementary and Intergrative Medicine, New York Presbyterian Hospital-Weill Cornell Medical College